Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam - Probes of CYP2C9, CYP1A2, and CYP3A4

被引:54
|
作者
Lilja, J. J.
Backman, J. T.
Neuvonen, P. J.
机构
[1] Univ Helsinki, Dept Clin Pharmacol, SF-00250 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, SF-00250 Helsinki, Finland
关键词
D O I
10.1038/sj.clpt.6100149
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Case reports suggest that cranberry juice can increase the anticoagulant effect of warfarin. We investigated the effects of cranberry juice on R-S-warfarin, tizanidine, and midazolam; probes of CYP2C9, CYP1A2, and CYP3A4. Ten healthy volunteers took 200 ml cranberry juice or water t.i.d. for 10 days. On day 5, they ingested 10 mg racemic R-S-warfarin, 1 mg tizanidine, and 0.5 mg midazolam, with juice or water, followed by monitoring of drug concentrations and thromboplastin time. Cranberry juice did not increase the peak plasma concentration or area under concentration-time curve (AUC) of the probe drugs or their metabolites, but slightly decreased (7%; P 0.051) the AUC of S-warfarin. Cranberry juice did not change the anticoagulant effect of warfarin. Daily ingestion of cranberry juice does not inhibit the activities of CYP2C9, CYP1A2, or CYP3A4. A pharmacokinetic mechanism for the cranberry juice-warfarin interaction seems unlikely.
引用
收藏
页码:833 / 839
页数:7
相关论文
共 50 条
  • [1] Effect of rivoceranib administered as 200 mg once daily on the pharmacokinetics of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 substrates
    Jang, Seong
    Wei, Xiaohui
    Meng, Xianzhang
    Reitano, Joseph
    Urity, Vinoo
    Park, Cheol Hee
    Strickland, Bill
    Lee, Grace
    Nguyen, David
    CANCER RESEARCH, 2024, 84 (07)
  • [2] The effects of buffer composition on the catalytic activities of human CYP1A2, CYP2C9, CYP2D6, and CYP3A4
    Gillespie, JS
    Binkley, SN
    Ring, BJ
    Wrighton, SA
    FASEB JOURNAL, 1998, 12 (04): : A144 - A144
  • [3] Effects of Panax notoginseng Saponins on the Activities of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 in Rats In Vivo
    Liu, Rui
    Qin, Mengnan
    Hang, Pengzhou
    Liu, Yan
    Zhang, Zhiren
    Liu, Gaofeng
    PHYTOTHERAPY RESEARCH, 2012, 26 (08) : 1113 - 1118
  • [4] SIMULTANEOUS EVALUATION OF CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP1A2 HYDROXYLATION CAPACITY IN HUMANS
    De Andres, F.
    Paulmichl, M.
    Llerena, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S61 - S61
  • [5] Effect of myricetin on cytochrome P450 isoforms CYP1A2, CYP2C9 and CYP3A4 in rats
    Guo, Yu-Jin
    Zheng, Shuang-li
    PHARMAZIE, 2014, 69 (04): : 306 - 310
  • [6] Effect of Dihydromyricetin on Cytochrome P450 Isoforms CYP1A2, CYP2C9 and CYP3A4 in Rats
    Huang, Yi
    Xu, Zhi-sheng
    Ye, Qiang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (10): : 1570 - 1574
  • [7] Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer
    Turner, P. Kellie
    Hall, Stephen D.
    Chapman, Sonya C.
    Rehmel, Jessica L.
    Royalty, Jane E.
    Guo, Yingying
    Kulanthaivel, Palaniappan
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (09) : 796 - 803
  • [8] Suppression of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 activity by a cocktail of inflammatory cytokines
    Foster, John
    Webber, Guy
    Ormsby, Terry
    Cheung, Yen-Ling
    Paul, Danny S.
    Webber, Colin
    Waring, Adrian
    DRUG METABOLISM REVIEWS, 2016, 48 : 89 - 89
  • [9] Pharmacogenetics of acenocoumarol:: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements
    Saraeva, R. B.
    Paskaleva, I. D.
    Doncheva, E.
    Eap, C. B.
    Ganev, V. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (06) : 641 - 649
  • [10] Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics
    Saiz-Rodriguez, Miriam
    Ochoa, Dolores
    Belmonte, Carmen
    Roman, Manuel
    Vieira de Lara, Danilo
    Zubiaur, Pablo
    Koller, Dora
    Mejia, Gina
    Abad-Santos, Francisco
    JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (04) : 522 - 531